TY - JOUR
T1 - Exploring the potential of neuroproteomics in Alzheimer's disease
AU - Uddin, Md Sahab
AU - Kabir, Md Tanvir
AU - Jakaria, Md
AU - Sobarzo-Sánchez, Eduardo
AU - Barreto, George E.
AU - Perveen, Asma
AU - Hafeez, Abdul
AU - Bin-Jumah, May N.
AU - Abdel-Daim, Mohamed M.
AU - Ashraf, Ghulam M.
N1 - Copyright© Bentham Science Publishers; For any queries, please email at [email protected].
PY - 2020
Y1 - 2020
N2 - Alzheimer's disease (AD) is progressive brain amyloidosis that damages brain regions associated with memory, thinking, behavioral and social skills. Neuropathologically, AD is characterized by intraneuronal hyperphosphorylated tau inclusions as neurofibrillary tangles (NFTs), and buildup of ex-tracellular amyloid-beta (Aβ) peptide as senile plaques. Several biomarker tests capturing these patholo-gies have been developed. However, for the full clinical expression of the neurodegenerative events of AD, there exist other central molecular pathways. In terms of understanding the unidentified underlying processes for the progression and development of AD, a complete comprehension of the structure and composition of atypical aggregation of proteins is essential. Presently, to aid the prognosis, diagnosis, detection, and development of drug targets in AD, neuroproteomics is elected as one of the leading essential tools for the efficient exploratory discovery of prospective biomarker candidates estimated to play a crucial role. Therefore, the aim of this review is to present the role of neuroproteomics to analyze the complexity of AD.
AB - Alzheimer's disease (AD) is progressive brain amyloidosis that damages brain regions associated with memory, thinking, behavioral and social skills. Neuropathologically, AD is characterized by intraneuronal hyperphosphorylated tau inclusions as neurofibrillary tangles (NFTs), and buildup of ex-tracellular amyloid-beta (Aβ) peptide as senile plaques. Several biomarker tests capturing these patholo-gies have been developed. However, for the full clinical expression of the neurodegenerative events of AD, there exist other central molecular pathways. In terms of understanding the unidentified underlying processes for the progression and development of AD, a complete comprehension of the structure and composition of atypical aggregation of proteins is essential. Presently, to aid the prognosis, diagnosis, detection, and development of drug targets in AD, neuroproteomics is elected as one of the leading essential tools for the efficient exploratory discovery of prospective biomarker candidates estimated to play a crucial role. Therefore, the aim of this review is to present the role of neuroproteomics to analyze the complexity of AD.
KW - Alzheimer Disease/diagnosis
KW - Amyloid beta-Peptides/analysis
KW - Biomarkers/analysis
KW - Humans
KW - Protein Aggregates
KW - Protein Aggregation, Pathological/diagnosis
KW - Proteomics
UR - http://www.scopus.com/inward/record.url?scp=85088832026&partnerID=8YFLogxK
U2 - 10.2174/1568026620666200603112030
DO - 10.2174/1568026620666200603112030
M3 - Review article
C2 - 32493192
AN - SCOPUS:85088832026
SN - 1568-0266
VL - 20
SP - 2263
EP - 2278
JO - Current Topics in Medicinal Chemistry
JF - Current Topics in Medicinal Chemistry
IS - 25
ER -